Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice

Authors

  • K Nomoto,

    1. Department of Pathology (I), Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • K Tsuneyama,

    Corresponding author
    1. Department of Pathology (I), Faculty of Medicine, University of Toyama, Toyama, Japan
    2. 21st Century COE Program, Faculty of Medicine, University of Toyama, Toyama, Japan
    • Department of Pathology (I), Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama City, Toyama 930-0194, Japan.
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • HO Abdel Aziz,

    1. Department of Pathology (I), Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • H Takahashi,

    1. Department of Pathology (I), Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • Y Murai,

    1. Department of Pathology (I), Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • Z-G Cui,

    1. Department of Pathology (I), Faculty of Medicine, University of Toyama, Toyama, Japan
    2. 21st Century COE Program, Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • M Fujimoto,

    1. Department of Japanese Oriental Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • I Kato,

    1. 21st Century COE Program, Faculty of Medicine, University of Toyama, Toyama, Japan
    2. Department of Biochemistry, Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • K Hiraga,

    1. Department of Biochemistry, Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • DK Hsu,

    1. Department of Dermatology, University of California, Davis, School of Medicine, Sacramento, California, USA
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • F-T Liu,

    1. Department of Dermatology, University of California, Davis, School of Medicine, Sacramento, California, USA
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.

  • Y Takano

    1. Department of Pathology (I), Faculty of Medicine, University of Toyama, Toyama, Japan
    Search for more papers by this author
    • The authors of this article declared they have no conflicts of interest.


Abstract

Galectin-3, a β-galactoside-binding animal lectin, is a multifunctional protein. Previous studies have suggested that galectin-3 may play an important role in inflammatory responses. Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a liver condition that may progress to end-stage liver disease and based on the known functions of galectin-3, it was hypothesized that galectin-3 might play a role in the development of NAFLD. Thus, this study investigated the role of galectin-3 in NAFLD by comparing galectin-3 knockout (gal3−/−) mice and wild-type (gal3+/+) mice. The livers of gal3−/− male mice at 6 months of age histologically displayed mild to severe fatty change. The liver weight per body weight ratio, serum alanine aminotransferase levels, liver triglyceride levels, and liver lipid peroxide in gal3−/− mice were significantly increased compared with those in gal3+/+ mice. Furthermore, the hepatic protein levels of advanced glycation end-products (AGE), receptor for AGE (RAGE), and peroxisome proliferator-activated receptor γ (PPARγ) were increased in gal3−/− mice relative to gal3+/+ mice. In conclusion, this study suggests that the absence of gal3 can cause clinico-pathological features in male mice similar to those of NAFLD. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Ancillary